Our first product candidate, ThermoDox^® uses our LTSL (lysolipid thermally sensitive liposome) technology to encapsulate the commonly used cancer drug doxorubicin. The heat-sensitive liposome rapidly changes structure when heated to 40°C-45°C, creating openings that release doxorubicin directly into and around the targeted tumor. ThermoDox is currently being evaluated in clinical studies for primary liver cancer.

Our second product candidate GEN-1, uses our TheraPlas™ technology platform to provide localized immunotherapy. GEN-1 is an interleukin-12 (IL-12) DNA plasmid vector formed into nanoparticles with a lipopolymeric delivery system. It is currently under evaluation for the treatment of ovarian cancer and has also demonstrated potential efficacy benefits in glioblastoma multiforme (GBM).